

Lucentis® and Avastin® - Wet AMD Intravitreal

These two drugs emerged from the promising technological platforms of monoclonal antibodies.

Technology platforms of monoclonal antibodies are promising and allow the development of many new drugs, given the ease to develop drugs for mediators or receptors that were previously identified.

Current conditions for these drugs are exposed in the corresponding chapter.

Future prospects about their use in AMD are essentially made by process innovation, with adoption of optimized therapeutic schemes of combined therapy and improvement of intra-eye drug delivery.

[View PDF](#)